IPO-bound bulk drug manufacturer Glenmark Life Sciences is on track to more than double its capacity over the next four years at a cumulative investment of over Rs 600 crore. Glenmark Life Sciences is …
( read original story …)
The Taiwan NEWS
IPO-bound bulk drug manufacturer Glenmark Life Sciences is on track to more than double its capacity over the next four years at a cumulative investment of over Rs 600 crore. Glenmark Life Sciences is …
( read original story …)